{
    "paper_id": "98928eeee2d49df093b3a8e397391310461fed44",
    "metadata": {
        "title": "ScienceDirect",
        "authors": [
            {
                "first": "M",
                "middle": [],
                "last": "Benucci",
                "suffix": "",
                "affiliation": {},
                "email": ":maurizio.benucci@uslcentro.toscana.it"
            }
        ]
    },
    "abstract": [],
    "body_text": [
        {
            "text": "La maladie \u00e0 coronavirus 2019 (COVID-19) se r\u00e9pand dans le monde entier, avec des centaines de milliers de cas. En Italie, 69 176 cas et 6 820 d\u00e9c\u00e8s \u00e9taient observ\u00e9s au 24 mars, de sorte que l'Association mondiale de la sant\u00e9 a officiellement d\u00e9clar\u00e9 que l'infection avait un caract\u00e8re pand\u00e9mique [1] . Le SARS-CoV-2 appartient \u00e0 la famille des virus \u00e0 ARN de type coronaviridiae (\u2424), qui est depuis longtemps reconnue comme responsable de l'infection des animaux de compagnie et de maladies respiratoires plus ou moins graves chez l'homme [c'est-\u00e0-dire le coronavirus 2 du syndrome respiratoire aigu s\u00e9v\u00e8re (SRAS-CoV-2)]. Ainsi, le coronavirus qui infecte l'homme peut \u00eatre divis\u00e9 en deux cat\u00e9gories: faiblement ou hautement pathog\u00e8ne [2] . Le SARS-CoV-2 est un nouveau \u2424-Coronavirus, probablement un virus recombinant originaire des chauves-souris. La recombinaison a lieu au sein de la glycoprot\u00e9ine Spike, qui reconna\u00eet un r\u00e9cepteur de surface cellulaire, permettant ainsi la transmission entre diff\u00e9rentes esp\u00e8ces [3] . La plupart des virus p\u00e9n\u00e8tre dans les cellules par endocytose m\u00e9di\u00e9e par un r\u00e9cepteur et dans le cas du COVID-19, on suppose que le r\u00e9cepteur de conversion de l'angiotensine 2 (ECA2) pourrait \u00eatre le r\u00e9cepteur utilis\u00e9 pour infecter les cellules pulmonaires. L'ECA2 est fortement exprim\u00e9 sur les cellules \u00e9pith\u00e9liales alv\u00e9olaires AT2 des poumons, particuli\u00e8rement sujettes aux infections virales [4] . Dans un rapport r\u00e9cent de Chine [5] , les caract\u00e9ristiques cliniques de COVID-19 peuvent \u00eatre traduites dans au moins trois mod\u00e8les cliniques: les patients asymptomatiques; les malades atteints d'une maladie l\u00e9g\u00e8re \u00e0 mod\u00e9r\u00e9e; les patients atteints d'une pneumonie grave qui doivent \u00eatre transf\u00e9r\u00e9s en soins intensifs (USI). Les sympt\u00f4mes les plus courants sont la fi\u00e8vre (g\u00e9n\u00e9ralement \u00e9lev\u00e9e chez au moins 70 % des patients), la toux s\u00e8che, la fatigue et un degr\u00e9 variable de dyspn\u00e9e. La dyspn\u00e9e se d\u00e9veloppe apr\u00e8s un d\u00e9lai m\u00e9dian de 8 jours \u00e0 partir du d\u00e9but de la maladie, avec DOI de l'article original : https://doi.org/10.1016/j.jbspin.2020.03.013. \u0b1d Ne pas utiliser, pour citation, la r\u00e9f\u00e9rence fran\u00e7 aise de cet article, mais la r\u00e9f\u00e9rence anglaise de Joint Bone Spine avec le doi ci-dessus. un d\u00e9lai m\u00e9dian d'admission \u00e0 l'USI de 5 jours \u00e0 partir du d\u00e9but de la dyspn\u00e9e. Jusqu'\u00e0 31 % des malades doivent \u00eatre transf\u00e9r\u00e9s dans une unit\u00e9 de soins intensifs [5] [6] [7] . Les malades au pronostic s\u00e9v\u00e8re pr\u00e9sentent une augmentation marqu\u00e9e des cytokines plasmatiques (syndrome d'orage cytokinique), et le cas \u00e9ch\u00e9ant une augmentation de la vitesse de s\u00e9dimentation et de la prot\u00e9ine C-r\u00e9active (CRP) [8] .",
            "cite_spans": [
                {
                    "start": 297,
                    "end": 300,
                    "text": "[1]",
                    "ref_id": null
                },
                {
                    "start": 736,
                    "end": 739,
                    "text": "[2]",
                    "ref_id": "BIBREF0"
                },
                {
                    "start": 1019,
                    "end": 1022,
                    "text": "[3]",
                    "ref_id": "BIBREF1"
                },
                {
                    "start": 1420,
                    "end": 1423,
                    "text": "[4]",
                    "ref_id": "BIBREF2"
                },
                {
                    "start": 1458,
                    "end": 1461,
                    "text": "[5]",
                    "ref_id": "BIBREF3"
                },
                {
                    "start": 2387,
                    "end": 2390,
                    "text": "[5]",
                    "ref_id": "BIBREF3"
                },
                {
                    "start": 2391,
                    "end": 2394,
                    "text": "[6]",
                    "ref_id": "BIBREF4"
                },
                {
                    "start": 2395,
                    "end": 2398,
                    "text": "[7]",
                    "ref_id": "BIBREF5"
                },
                {
                    "start": 2629,
                    "end": 2632,
                    "text": "[8]",
                    "ref_id": "BIBREF6"
                }
            ],
            "ref_spans": [],
            "section": ""
        },
        {
            "text": "Jusqu'\u00e0 pr\u00e9sent, il n'existe pas de traitement antiviral sp\u00e9cifique pour le COVID-19. Toutefois, \u00e0 la lumi\u00e8re de la compr\u00e9hension croissante de la biologie du SRAS-CoV-2 et de COVID-19, plusieurs m\u00e9dicaments couramment utilis\u00e9s en rhumatologie ont \u00e9t\u00e9 propos\u00e9s comme traitements potentiels pour COVID-19. La chloroquine et l'hydroxychloroquine (HCQ) sont des agents antipaludiques \u00e0 activit\u00e9 immuno-modulatrice largement utilis\u00e9s en rhumatologie. Ces agents pr\u00e9sentent \u00e9galement une activit\u00e9 antivirale bien connue, \u00e0 large spectre [9] . Ces m\u00e9dicaments agissent en augmentant le pH endosomal et en inhibant un Toll-like R\u00e9depteur (TLR)pour interf\u00e9rer avec la fusion virale/cellulaire, ainsi qu'en interf\u00e9rant avec la glycosylation de l'ACE2, qui repr\u00e9sente le r\u00e9cepteur cellulaire du virus [10] . Des \u00e9tudes in vitro ont d\u00e9montr\u00e9 une activit\u00e9 antivirale contre le SRAS-CoV-2 \u00e0 des concentrations pouvant \u00eatre obtenues de mani\u00e8re th\u00e9rapeutique pour les doses utilis\u00e9es en rhumatologie. De plus, l'activit\u00e9 immunomodulatrice de ces agents, qui limite l'activation immunitaire syst\u00e9mique associ\u00e9e \u00e0 la COVID-19, pourrait agir en synergie avec les propri\u00e9t\u00e9s antivirales [11] . De nombreuses \u00e9tudes cliniques men\u00e9es en Chine sur des patients trait\u00e9s par COVID-19 ont d\u00e9montr\u00e9 la sup\u00e9riorit\u00e9 du traitement par l'HCQ par rapport au placebo pour inhiber l'exacerbation de la pneumonie, am\u00e9liorer les donn\u00e9es d'imagerie, favoriser un \u00e9tat viral n\u00e9gatif et r\u00e9duire l'\u00e9volution de la maladie en l'absence de r\u00e9actions ind\u00e9sirables graves [12] . Par cons\u00e9quent, plusieurs agences m\u00e9dicales r\u00e9glementaires (dont la Chine et l'Italie) incluent la chloroquine et l' HCQ dans les recommandations pour le traitement de la COVID-19 [13] [14] . Une \u00e9tude fran\u00e7 aise r\u00e9cente portant sur 36 patients a indiqu\u00e9 que l'ajout d'azithromycine \u00e0 l' HCQ permettait de r\u00e9duire davantage la charge virale [15] . En outre, le r\u00f4le de l' HCQ a \u00e9t\u00e9 soulign\u00e9 dans le traitement de l'infection par COVID pendant la grossesse [16] . Le d\u00e9veloppement du syndrome de lib\u00e9ration de cytokines et des anomalies des lymphocytes T joue un r\u00f4le cl\u00e9 dans la progression de COVID-19. Dans ces circonstances, la stimulation virale persistante entra\u00eene une augmentation significative des cytokines circulantes telles que l'interleukine (I)L-6, l'IL-10 et le TNF-\u2423. Les taux de ces cytokines sont en corr\u00e9lation n\u00e9gative avec le nombre absolu de lymphocytes, ce qui provoque https://doi.org/10.1016/j.rhum.2020.03.010 1169-8330/\u00a9 2020 Soci\u00e9t\u00e9 Fran\u00e7 aise de Rhumatologie. Publi\u00e9 par Elsevier Masson SAS. Tous droits r\u00e9serv\u00e9s. l'\u00e9puisement et l'apoptose des lymphocytes T qui peuvent d\u00e9clencher des dommages tissulaires inflammatoires [17] .",
            "cite_spans": [
                {
                    "start": 532,
                    "end": 535,
                    "text": "[9]",
                    "ref_id": "BIBREF7"
                },
                {
                    "start": 791,
                    "end": 795,
                    "text": "[10]",
                    "ref_id": "BIBREF8"
                },
                {
                    "start": 1168,
                    "end": 1172,
                    "text": "[11]",
                    "ref_id": "BIBREF9"
                },
                {
                    "start": 1529,
                    "end": 1533,
                    "text": "[12]",
                    "ref_id": "BIBREF10"
                },
                {
                    "start": 1716,
                    "end": 1720,
                    "text": "[13]",
                    "ref_id": "BIBREF11"
                },
                {
                    "start": 1721,
                    "end": 1725,
                    "text": "[14]",
                    "ref_id": "BIBREF12"
                },
                {
                    "start": 1877,
                    "end": 1881,
                    "text": "[15]",
                    "ref_id": "BIBREF13"
                },
                {
                    "start": 1992,
                    "end": 1996,
                    "text": "[16]",
                    "ref_id": "BIBREF14"
                },
                {
                    "start": 2686,
                    "end": 2690,
                    "text": "[17]",
                    "ref_id": "BIBREF15"
                }
            ],
            "ref_spans": [],
            "section": ""
        },
        {
            "text": "L'IL-6 joue un r\u00f4le central dans la pathogen\u00e8se du syndrome de lib\u00e9ration de cytokines associ\u00e9 au SRAS-CoV-2 et, par cons\u00e9quent, le tocilizumab, un anticorps monoclonal humanis\u00e9 contre le r\u00e9cepteur de l'IL-6, a gagn\u00e9 en int\u00e9r\u00eat comme traitement potentiel de la COVID-19. Une \u00e9tude r\u00e9trospective portant sur 21 patients atteints de COVID-19 grave a montr\u00e9 qu'un traitement par le tocilizumab \u00e0 raison de 4 \u00e0 8 mg/kg am\u00e9liore la saturation en oxyg\u00e8ne et les anomalies visibles au scanner, le nombre de lymphocytes et normalise les niveaux de PCR chez la plupart des patients [18] . L'essai clinique randomis\u00e9 sur la s\u00e9curit\u00e9 et l'efficacit\u00e9 du tocilizumab dans le COVID-19 est toujours en cours (ChiCTR2000029765). Les recommandations chinoises ont introduit le tocilizumab comme option pour les patients souffrant d'une maladie pulmonaire bilat\u00e9rale \u00e9tendue ou pour les patients gravement malades pr\u00e9sentant des taux \u00e9lev\u00e9s d'IL-6 [14] . Sur la base des donn\u00e9es chinoises, l'AIFA a lanc\u00e9 le 17 mars une \u00e9tude prospective sur l'utilisation du tocilizumab pour la maladie COVID-19 dans un groupe de patients qui pr\u00e9sentent une insuffisance respiratoire intub\u00e9e dans les premi\u00e8res 24 heures, en plus d'une \u00e9tude qui recueille des donn\u00e9es sur les patients d\u00e9j\u00e0 trait\u00e9s, intub\u00e9s ou non, avant l'approbation du registre (TOCIVID). Aucune donn\u00e9e n'est encore disponible sur l'introduction du tocilizumab chez les patients COVID-19 pr\u00e9sentant des stades pr\u00e9coces d'insuffisance respiratoire, mais dans la litt\u00e9rature rhumatologique, l'int\u00e9r\u00eat majeur d'un traitement pr\u00e9coce par ce m\u00e9dicament sur la progression des dommages dus \u00e0 l'inflammation a \u00e9t\u00e9 bien document\u00e9. Certaines directives r\u00e9gionales [13] ont introduit le dosage de l'IL-6 avec un seuil sup\u00e9rieur \u00e0 20 pg/mL comme crit\u00e8re de traitement par le tocilizumab. Une \u00e9tude portant sur 188 patients aura lieu en Chine du 10 f\u00e9vrier au 10 mai. Le laboratoire Roche a d\u00e9clar\u00e9 lundi 16 mars qu'il avait fait don en f\u00e9vrier d'une valeur 14 millions de yuans (2,2 millions de dollars) de tocilizumab. Sur la base de ces donn\u00e9es, une \u00e9tude sera lanc\u00e9e aux Etats-Unis et en France, utilisant un autre anticorps monoclonal anti-r\u00e9cepteur IL-6, le sarilumab, pour le COVID-19.",
            "cite_spans": [
                {
                    "start": 573,
                    "end": 577,
                    "text": "[18]",
                    "ref_id": "BIBREF16"
                },
                {
                    "start": 930,
                    "end": 934,
                    "text": "[14]",
                    "ref_id": "BIBREF12"
                },
                {
                    "start": 1690,
                    "end": 1694,
                    "text": "[13]",
                    "ref_id": "BIBREF11"
                }
            ],
            "ref_spans": [],
            "section": ""
        },
        {
            "text": "Le SRAS-CoV-2 pr\u00e9sente plusieurs similitudes avec le SRAS-CoV, la souche de coronavirus responsable de la pand\u00e9mie de SRAS de 2002. Les deux virus utilisent les prot\u00e9ines Spike (S) pour engager leur r\u00e9cepteur cellulaire, ACE2, dans l'invasion cellulaire [19] . L'expression de l'ACE2 est r\u00e9gul\u00e9e \u00e0 la hausse par l'infection par le CoV-2 du SRAS et la stimulation des cytokines inflammatoires [20] . Dans l'infection par le SRAS-CoV, les prot\u00e9ines S peuvent induire la perte de l'ectodomaine de l'ACE2, un processus \u00e9troitement li\u00e9 \u00e0 la production de TNF\u2423 [21] . Cette perte d'activit\u00e9 de l'ACE2 caus\u00e9e par l'excr\u00e9tion a \u00e9t\u00e9 associ\u00e9e \u00e0 des l\u00e9sions pulmonaires en raison de l'activit\u00e9 accrue du syst\u00e8me r\u00e9nine-angiotensine [22] . Bien que principalement d\u00e9montr\u00e9e pour le SRAS-CoV, l'homologie entre les structures des prot\u00e9ines S sugg\u00e8re que la prot\u00e9ine S du SARSCoV-2 pourrait \u00e9galement pr\u00e9senter un m\u00e9canisme similaire [23] . L'augmentation de la production de TNF\u2423 pourrait donc faciliter l'infection virale et causer des dommages aux organes. En effet, un traitement anti-TNF\u2423 a \u00e9t\u00e9 sugg\u00e9r\u00e9 comme option th\u00e9rapeutique possible dans le cadre de COVID-19 [24] et un essai randomis\u00e9 \u00e9tudiant l'adalimumab dans COVID-19 a r\u00e9cemment \u00e9t\u00e9 enregistr\u00e9 (ChiCTR2000030089).",
            "cite_spans": [
                {
                    "start": 254,
                    "end": 258,
                    "text": "[19]",
                    "ref_id": "BIBREF17"
                },
                {
                    "start": 392,
                    "end": 396,
                    "text": "[20]",
                    "ref_id": "BIBREF18"
                },
                {
                    "start": 555,
                    "end": 559,
                    "text": "[21]",
                    "ref_id": "BIBREF19"
                },
                {
                    "start": 721,
                    "end": 725,
                    "text": "[22]",
                    "ref_id": "BIBREF20"
                },
                {
                    "start": 920,
                    "end": 924,
                    "text": "[23]",
                    "ref_id": "BIBREF21"
                },
                {
                    "start": 1156,
                    "end": 1160,
                    "text": "[24]",
                    "ref_id": "BIBREF22"
                }
            ],
            "ref_spans": [],
            "section": ""
        },
        {
            "text": "Par ailleurs, l'IL-1 joue \u00e9galement un r\u00f4le essentiel dans le syndrome de lib\u00e9ration de cytokines, et elle pourrait \u00eatre impliqu\u00e9e dans la pneumonie interstitielle de COVID-19. De plus, les donn\u00e9es d'un essai de phase 3 avec anakinra, un inhibiteur de l'IL-1, dans la septic\u00e9mie, montrent des avantages anti-inflammatoires en l'absence d'\u00e9v\u00e9nements ind\u00e9sirables [25] . L'endocytose d\u00e9pendante de la clathrine est cruciale pour l'invasion virale des pneumocytes [26] . Ce processus est favoris\u00e9 par les membres de la famille des kinases (NAK), qui ont \u00e9t\u00e9 propos\u00e9s pour limiter le trafic viral intracellulaire. Les inhibiteurs de la tyrosine kinase, destin\u00e9s aux membres de la famille NAK, ont montr\u00e9 une bonne activit\u00e9 antivirale in vitro [27] . Les inhibiteurs JAK, dont le baricitinib, le ruxolitinib et le fedratinib, montrent la capacit\u00e9 d'inhiber la NAK, limitant \u00e9galement la r\u00e9ponse inflammatoire syst\u00e9mique et la production de cytokines par l'inhibition de la voie canonique JAK-STAT [28] . Bien que le baricitinib soit le seul inhibiteur de la voie JAK qui atteint des concentrations plasmatiques suffisantes pour inhiber les membres de la NAK \u00e0 des doses th\u00e9rapeutiques et bien tol\u00e9r\u00e9es [29] , le seul m\u00e9dicament actuellement \u00e9tudi\u00e9 dans le cadre de la COVID-19 est le ruxolitinib (ChiCTR2000029580). Les inqui\u00e9tudes concernant ces traitements d\u00e9coulent du fait que dans les premiers stades de la r\u00e9ponse inn\u00e9e \u00e0 COVID-19, et aux virus en g\u00e9n\u00e9ral, la famille des interf\u00e9rons joue un r\u00f4le important dans la r\u00e9ponse rapide \u00e0 l'agent pathog\u00e8ne, et nous connaissons la capacit\u00e9 du syst\u00e8me JAK/STAT \u00e0 r\u00e9duire la r\u00e9ponse du syst\u00e8me IFN qui est une explication \u00e0 la fr\u00e9quence plus \u00e9lev\u00e9e d'infections herp\u00e9tiques observ\u00e9e avec ces traitements [30] . Cependant, une \u00e9tude pilote ouverte (ClinicalTrials.gov:NCT04320277) a d\u00e9but\u00e9 le 24 mars dans le but d'\u00e9valuer le pourcentage de patients qui ont besoin de soins intensifs.",
            "cite_spans": [
                {
                    "start": 362,
                    "end": 366,
                    "text": "[25]",
                    "ref_id": "BIBREF23"
                },
                {
                    "start": 461,
                    "end": 465,
                    "text": "[26]",
                    "ref_id": "BIBREF24"
                },
                {
                    "start": 739,
                    "end": 743,
                    "text": "[27]",
                    "ref_id": "BIBREF25"
                },
                {
                    "start": 992,
                    "end": 996,
                    "text": "[28]",
                    "ref_id": "BIBREF26"
                },
                {
                    "start": 1197,
                    "end": 1201,
                    "text": "[29]",
                    "ref_id": "BIBREF27"
                },
                {
                    "start": 1746,
                    "end": 1750,
                    "text": "[30]",
                    "ref_id": "BIBREF28"
                }
            ],
            "ref_spans": [],
            "section": ""
        },
        {
            "text": "L'\u00e9tat actuel montre que des perspectives anciennes et nouvelles s'ouvrent pour les m\u00e9dicaments anti-rhumatismaux dans le traitement de cette pand\u00e9mie, et de nombreux groupes italiens de rhumatologie [31] luttent pour apporter leur contribution dans ce qui semble \u00eatre une pathologie aux aspects multidisciplinaires. La physiopathologie de certaines maladies rhumatismales inflammatoires et l'examen des effets ind\u00e9sirables li\u00e9s aux m\u00e9dicaments peuvent aider \u00e0 faire des choix th\u00e9rapeutiques au cours de cette pand\u00e9mie du XXI e si\u00e8cle.",
            "cite_spans": [
                {
                    "start": 200,
                    "end": 204,
                    "text": "[31]",
                    "ref_id": "BIBREF29"
                }
            ],
            "ref_spans": [],
            "section": ""
        },
        {
            "text": "Les auteurs d\u00e9clarent ne pas avoir de liens d'int\u00e9r\u00eats.",
            "cite_spans": [],
            "ref_spans": [],
            "section": "D\u00e9claration de liens d'int\u00e9r\u00eats"
        }
    ],
    "bib_entries": {
        "BIBREF0": {
            "ref_id": "b0",
            "title": "Pathogenic human coronavirus infections: causes and consequences of cytokine storm and immunopathology",
            "authors": [
                {
                    "first": "R",
                    "middle": [],
                    "last": "Channappanavar",
                    "suffix": ""
                },
                {
                    "first": "S",
                    "middle": [],
                    "last": "Perlman",
                    "suffix": ""
                }
            ],
            "year": 2017,
            "venue": "Semin Immunopathol",
            "volume": "39",
            "issn": "",
            "pages": "529--568",
            "other_ids": {}
        },
        "BIBREF1": {
            "ref_id": "b1",
            "title": "Cross-species transmission of the newly identified coronavirus 2019-nCoV",
            "authors": [
                {
                    "first": "W",
                    "middle": [],
                    "last": "Ji",
                    "suffix": ""
                },
                {
                    "first": "W",
                    "middle": [],
                    "last": "Wang",
                    "suffix": ""
                },
                {
                    "first": "X",
                    "middle": [],
                    "last": "Zhao",
                    "suffix": ""
                }
            ],
            "year": 2020,
            "venue": "J Med Virol",
            "volume": "92",
            "issn": "",
            "pages": "433--473",
            "other_ids": {}
        },
        "BIBREF2": {
            "ref_id": "b2",
            "title": "Single-cell RNA expression profiling of ACE2, the putative receptor of Wuhan 2019-nCov",
            "authors": [
                {
                    "first": "Y",
                    "middle": [],
                    "last": "Zhao",
                    "suffix": ""
                },
                {
                    "first": "Z",
                    "middle": [],
                    "last": "Zhao",
                    "suffix": ""
                },
                {
                    "first": "Y",
                    "middle": [],
                    "last": "Wang",
                    "suffix": ""
                }
            ],
            "year": null,
            "venue": "",
            "volume": "2020",
            "issn": "",
            "pages": "",
            "other_ids": {
                "DOI": [
                    "10.1101/2020.01.26.919985"
                ]
            }
        },
        "BIBREF3": {
            "ref_id": "b3",
            "title": "Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China",
            "authors": [
                {
                    "first": "C",
                    "middle": [],
                    "last": "Huang",
                    "suffix": ""
                },
                {
                    "first": "Y",
                    "middle": [],
                    "last": "Wang",
                    "suffix": ""
                },
                {
                    "first": "X",
                    "middle": [],
                    "last": "Li",
                    "suffix": ""
                }
            ],
            "year": 2020,
            "venue": "Lancet",
            "volume": "395",
            "issn": "",
            "pages": "497--506",
            "other_ids": {
                "DOI": [
                    "file:/localhost/opt/grobid/grobid-home/tmp/dx.doi.org/10.1101/2020.01.26.919985"
                ]
            }
        },
        "BIBREF4": {
            "ref_id": "b4",
            "title": "Clinical findings in a group of patients infected with the 2019 novel coronavirus (SARS-Cov-2) outside of Wuhan, China: retrospective case series",
            "authors": [
                {
                    "first": "X",
                    "middle": [
                        "W"
                    ],
                    "last": "Xu",
                    "suffix": ""
                },
                {
                    "first": "X",
                    "middle": [
                        "X"
                    ],
                    "last": "Wu",
                    "suffix": ""
                },
                {
                    "first": "X",
                    "middle": [
                        "G"
                    ],
                    "last": "Jiang",
                    "suffix": ""
                }
            ],
            "year": 2020,
            "venue": "BMJ",
            "volume": "368",
            "issn": "",
            "pages": "",
            "other_ids": {
                "DOI": [
                    "10.1136/bmj.m606"
                ]
            }
        },
        "BIBREF5": {
            "ref_id": "b5",
            "title": "Clinical course and mortality of adult in patients with COVID-19 in Wuhan, China: a retrospective cohort study",
            "authors": [
                {
                    "first": "F",
                    "middle": [],
                    "last": "Zhou",
                    "suffix": ""
                },
                {
                    "first": "T",
                    "middle": [],
                    "last": "Yu",
                    "suffix": ""
                },
                {
                    "first": "G",
                    "middle": [],
                    "last": "Fan",
                    "suffix": ""
                }
            ],
            "year": 2020,
            "venue": "The Lancet",
            "volume": "",
            "issn": "",
            "pages": "30566--30569",
            "other_ids": {
                "DOI": [
                    "file:/localhost/opt/grobid/grobid-home/tmp/dx.doi.org/10.1136/bmj.m606"
                ]
            }
        },
        "BIBREF6": {
            "ref_id": "b6",
            "title": "Effective treatment of severe COVID-19 patients with tocilizumab",
            "authors": [
                {
                    "first": "X",
                    "middle": [],
                    "last": "Xu",
                    "suffix": ""
                },
                {
                    "first": "M",
                    "middle": [],
                    "last": "Han",
                    "suffix": ""
                },
                {
                    "first": "T",
                    "middle": [],
                    "last": "Li",
                    "suffix": ""
                },
                {
                    "first": "W",
                    "middle": [],
                    "last": "Sun",
                    "suffix": ""
                },
                {
                    "first": "D",
                    "middle": [],
                    "last": "Wang",
                    "suffix": ""
                },
                {
                    "first": "B",
                    "middle": [],
                    "last": "Fu",
                    "suffix": ""
                }
            ],
            "year": null,
            "venue": "",
            "volume": "",
            "issn": "",
            "pages": "",
            "other_ids": {
                "DOI": [
                    "file:/localhost/opt/grobid/grobid-home/tmp/dx.doi.org/10.1016/S0140-6726(20)30566-3"
                ]
            }
        },
        "BIBREF7": {
            "ref_id": "b7",
            "title": "Recycling of chloroquine and its hydroxyl analogue to face bacterial, fungal and viral infections in the 21st century",
            "authors": [
                {
                    "first": "J-M",
                    "middle": [],
                    "last": "Rolain",
                    "suffix": ""
                },
                {
                    "first": "P",
                    "middle": [],
                    "last": "Colson",
                    "suffix": ""
                },
                {
                    "first": "D",
                    "middle": [],
                    "last": "Raoult",
                    "suffix": ""
                }
            ],
            "year": 2007,
            "venue": "Int J Antimicrob Agents",
            "volume": "30",
            "issn": "",
            "pages": "297--308",
            "other_ids": {}
        },
        "BIBREF8": {
            "ref_id": "b8",
            "title": "Chloroquine is a potent inhibitor of SARS coronavirus infection and spread",
            "authors": [
                {
                    "first": "M",
                    "middle": [
                        "J"
                    ],
                    "last": "Vincent",
                    "suffix": ""
                },
                {
                    "first": "E",
                    "middle": [],
                    "last": "Bergeron",
                    "suffix": ""
                },
                {
                    "first": "S",
                    "middle": [],
                    "last": "Benjannet",
                    "suffix": ""
                }
            ],
            "year": 2005,
            "venue": "Virology journal",
            "volume": "2",
            "issn": "",
            "pages": "",
            "other_ids": {}
        },
        "BIBREF9": {
            "ref_id": "b9",
            "title": "Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro",
            "authors": [
                {
                    "first": "M",
                    "middle": [],
                    "last": "Wang",
                    "suffix": ""
                },
                {
                    "first": "R",
                    "middle": [],
                    "last": "Cao",
                    "suffix": ""
                },
                {
                    "first": "L",
                    "middle": [],
                    "last": "Zhang",
                    "suffix": ""
                }
            ],
            "year": 2020,
            "venue": "Cell research",
            "volume": "30",
            "issn": "",
            "pages": "269--71",
            "other_ids": {}
        },
        "BIBREF10": {
            "ref_id": "b10",
            "title": "Breakthrough: Chloroquine phosphate has shown apparent efficacy in treatment of COVID-19 associated pneumonia in clinical studies",
            "authors": [
                {
                    "first": "J",
                    "middle": [],
                    "last": "Gao",
                    "suffix": ""
                },
                {
                    "first": "Z",
                    "middle": [],
                    "last": "Tian",
                    "suffix": ""
                },
                {
                    "first": "X",
                    "middle": [],
                    "last": "Yang",
                    "suffix": ""
                }
            ],
            "year": 2020,
            "venue": "BioScience Trends",
            "volume": "14",
            "issn": "",
            "pages": "72--75",
            "other_ids": {}
        },
        "BIBREF11": {
            "ref_id": "b11",
            "title": "Linee guida sulla gestione terapeutica e di supporto per pazienti con infezione da coronavirus COVID-19. SIMIT, Edizione marzo 2020",
            "authors": [
                {
                    "first": "S",
                    "middle": [
                        "R"
                    ],
                    "last": "Lombardia",
                    "suffix": ""
                }
            ],
            "year": 2020,
            "venue": "",
            "volume": "",
            "issn": "",
            "pages": "",
            "other_ids": {}
        },
        "BIBREF12": {
            "ref_id": "b12",
            "title": "Diagnosis and treatment protocol for novel coronavirus pneumonia",
            "authors": [
                {
                    "first": "",
                    "middle": [],
                    "last": "Nhcomaha",
                    "suffix": ""
                }
            ],
            "year": 2020,
            "venue": "",
            "volume": "",
            "issn": "",
            "pages": "",
            "other_ids": {}
        },
        "BIBREF13": {
            "ref_id": "b13",
            "title": "Hydroxychloroquine and azithromycin as a treatment of COVID-19: results of an openlabel non-randomized clinical trial",
            "authors": [
                {
                    "first": "P",
                    "middle": [],
                    "last": "Gautret",
                    "suffix": ""
                },
                {
                    "first": "J",
                    "middle": [
                        "C"
                    ],
                    "last": "Lagier",
                    "suffix": ""
                },
                {
                    "first": "P",
                    "middle": [],
                    "last": "Parola",
                    "suffix": ""
                }
            ],
            "year": null,
            "venue": "Int J Antimicrobl Agents",
            "volume": "2020",
            "issn": "",
            "pages": "",
            "other_ids": {
                "DOI": [
                    "10.1016/j.ijantimicag.2020.105949"
                ]
            }
        },
        "BIBREF14": {
            "ref_id": "b14",
            "title": "COVID-19: a recommendation to examine the effect of hydroxychloroquine in preventing infection and progression",
            "authors": [
                {
                    "first": "D",
                    "middle": [],
                    "last": "Zhou",
                    "suffix": ""
                },
                {
                    "first": "S",
                    "middle": [
                        "M"
                    ],
                    "last": "Dai",
                    "suffix": ""
                },
                {
                    "first": "Q",
                    "middle": [],
                    "last": "Tong",
                    "suffix": ""
                }
            ],
            "year": 2020,
            "venue": "J Antimicrob Chemother",
            "volume": "",
            "issn": "",
            "pages": "",
            "other_ids": {
                "DOI": [
                    "file:/localhost/opt/grobid/grobid-home/tmp/dx.doi.org/10.1016/j.ijantimicag.2020.105949"
                ]
            }
        },
        "BIBREF15": {
            "ref_id": "b15",
            "title": "Reduction and Functional Exhaustion of T Cells in Patients with Coronavirus Disease 2019 (COVID-19)",
            "authors": [
                {
                    "first": "B",
                    "middle": [],
                    "last": "Diao",
                    "suffix": ""
                },
                {
                    "first": "C",
                    "middle": [],
                    "last": "Wang",
                    "suffix": ""
                },
                {
                    "first": "Y",
                    "middle": [],
                    "last": "Tan",
                    "suffix": ""
                }
            ],
            "year": null,
            "venue": "",
            "volume": "2020",
            "issn": "",
            "pages": "",
            "other_ids": {
                "DOI": [
                    "file:/localhost/opt/grobid/grobid-home/tmp/dx.doi.org/10.1093/jac/dkaa114"
                ]
            }
        },
        "BIBREF16": {
            "ref_id": "b16",
            "title": "Effective Treatment of Severe COVID-19 Patients with Tocilizumab",
            "authors": [
                {
                    "first": "X",
                    "middle": [],
                    "last": "Xu",
                    "suffix": ""
                },
                {
                    "first": "M",
                    "middle": [],
                    "last": "Han",
                    "suffix": ""
                },
                {
                    "first": "T",
                    "middle": [],
                    "last": "Li",
                    "suffix": ""
                },
                {
                    "first": "W",
                    "middle": [],
                    "last": "Sun",
                    "suffix": ""
                },
                {
                    "first": "D",
                    "middle": [],
                    "last": "Wang",
                    "suffix": ""
                },
                {
                    "first": "B",
                    "middle": [],
                    "last": "Fu",
                    "suffix": ""
                }
            ],
            "year": 2020,
            "venue": "",
            "volume": "",
            "issn": "",
            "pages": "",
            "other_ids": {
                "DOI": [
                    "file:/localhost/opt/grobid/grobid-home/tmp/dx.doi.org/10.1101/2020.02.18.20024364"
                ]
            }
        },
        "BIBREF17": {
            "ref_id": "b17",
            "title": "SARS-CoV-2 cell entry depends on ace2 and tmprss2 and is blocked by a clinically proven protease inhibitor",
            "authors": [
                {
                    "first": "M",
                    "middle": [],
                    "last": "Hoffmann",
                    "suffix": ""
                },
                {
                    "first": "H",
                    "middle": [],
                    "last": "Kleine-Weber",
                    "suffix": ""
                },
                {
                    "first": "S",
                    "middle": [],
                    "last": "Schroeder",
                    "suffix": ""
                }
            ],
            "year": null,
            "venue": "Cell",
            "volume": "2020",
            "issn": "",
            "pages": "",
            "other_ids": {
                "DOI": [
                    "10.1016/j.cell.2020.02.052"
                ]
            }
        },
        "BIBREF18": {
            "ref_id": "b18",
            "title": "Increasing Host Cellular Receptor-Angiotensin-Converting Enzyme 2 (ACE2) Expression by Coronavirus may Facilitate 2019-nCoV Infection",
            "authors": [
                {
                    "first": "P-H",
                    "middle": [],
                    "last": "Wang",
                    "suffix": ""
                }
            ],
            "year": null,
            "venue": "",
            "volume": "2020",
            "issn": "",
            "pages": "",
            "other_ids": {
                "DOI": [
                    "file:/localhost/opt/grobid/grobid-home/tmp/dx.doi.org/10.1016/j.cell.2020.02.052"
                ]
            }
        },
        "BIBREF19": {
            "ref_id": "b19",
            "title": "Modulation of TNF-(-converting enzyme by the spike protein of SARS-CoV and ACE2 induces TNF-(production and facilitates viral entry",
            "authors": [
                {
                    "first": "S",
                    "middle": [],
                    "last": "Haga",
                    "suffix": ""
                },
                {
                    "first": "N",
                    "middle": [],
                    "last": "Yamamoto",
                    "suffix": ""
                },
                {
                    "first": "C",
                    "middle": [],
                    "last": "Nakai-Murakami",
                    "suffix": ""
                }
            ],
            "year": 2008,
            "venue": "Proceedings of the National Academy of Sciences",
            "volume": "105",
            "issn": "22",
            "pages": "7809--7823",
            "other_ids": {
                "DOI": [
                    "file:/localhost/opt/grobid/grobid-home/tmp/dx.doi.org/10.1101/2020.02.24.963348"
                ]
            }
        },
        "BIBREF20": {
            "ref_id": "b20",
            "title": "Angiotensin-converting enzyme 2 protects from severe acute lung failure",
            "authors": [
                {
                    "first": "Y",
                    "middle": [],
                    "last": "Imai",
                    "suffix": ""
                },
                {
                    "first": "K",
                    "middle": [],
                    "last": "Kuba",
                    "suffix": ""
                },
                {
                    "first": "S",
                    "middle": [],
                    "last": "Rao",
                    "suffix": ""
                }
            ],
            "year": 2005,
            "venue": "Nature",
            "volume": "436",
            "issn": "",
            "pages": "112--118",
            "other_ids": {}
        },
        "BIBREF21": {
            "ref_id": "b21",
            "title": "Understanding SARS-CoV-2-Mediated Inflammatory Responses: FromMechanisms to Potential Therapeutic Tools",
            "authors": [
                {
                    "first": "Y",
                    "middle": [],
                    "last": "Fu",
                    "suffix": ""
                },
                {
                    "first": "Y",
                    "middle": [],
                    "last": "Cheng",
                    "suffix": ""
                },
                {
                    "first": "Y",
                    "middle": [],
                    "last": "Wu",
                    "suffix": ""
                }
            ],
            "year": 2020,
            "venue": "Virologica Sinica",
            "volume": "",
            "issn": "",
            "pages": "",
            "other_ids": {
                "DOI": [
                    "10.1007/s12250-020-00207-4"
                ]
            }
        },
        "BIBREF22": {
            "ref_id": "b22",
            "title": "Regulation of interferon production as a potential strategy for COVID-19 treatment",
            "authors": [
                {
                    "first": "X",
                    "middle": [],
                    "last": "Deng",
                    "suffix": ""
                },
                {
                    "first": "X",
                    "middle": [],
                    "last": "Yu",
                    "suffix": ""
                },
                {
                    "first": "Pei",
                    "middle": [
                        "J"
                    ],
                    "last": "",
                    "suffix": ""
                }
            ],
            "year": 2003,
            "venue": "",
            "volume": "",
            "issn": "",
            "pages": "",
            "other_ids": {
                "DOI": [
                    "file:/localhost/opt/grobid/grobid-home/tmp/dx.doi.org/10.1007/s12250-020-00207-4"
                ]
            }
        },
        "BIBREF23": {
            "ref_id": "b23",
            "title": "Interleukin-1 receptor blockade is associated with reduced mortality in sepsis patients with features of macrophage activation syndrome",
            "authors": [
                {
                    "first": "B",
                    "middle": [],
                    "last": "Shakoory",
                    "suffix": ""
                },
                {
                    "first": "J",
                    "middle": [
                        "A"
                    ],
                    "last": "Carcillo",
                    "suffix": ""
                },
                {
                    "first": "W",
                    "middle": [
                        "W"
                    ],
                    "last": "Chatham",
                    "suffix": ""
                }
            ],
            "year": 2016,
            "venue": "Crit Care Med",
            "volume": "44",
            "issn": "",
            "pages": "275--81",
            "other_ids": {}
        },
        "BIBREF24": {
            "ref_id": "b24",
            "title": "Molecular immune pathogenesis and diagnosis of COVID-19",
            "authors": [
                {
                    "first": "X",
                    "middle": [],
                    "last": "Li",
                    "suffix": ""
                },
                {
                    "first": "M",
                    "middle": [],
                    "last": "Geng",
                    "suffix": ""
                },
                {
                    "first": "Y",
                    "middle": [],
                    "last": "Peng",
                    "suffix": ""
                }
            ],
            "year": null,
            "venue": "J Pharmaceut Anal",
            "volume": "2020",
            "issn": "",
            "pages": "",
            "other_ids": {
                "DOI": [
                    "10.1016/j.jpha.2020.03.001"
                ]
            }
        },
        "BIBREF25": {
            "ref_id": "b25",
            "title": "Feasibility and biological rationale of repurposing sunitinib and erlotinib for dengue treatment",
            "authors": [
                {
                    "first": "S-Y",
                    "middle": [],
                    "last": "Pu",
                    "suffix": ""
                },
                {
                    "first": "Xiao",
                    "middle": [
                        "F"
                    ],
                    "last": "Schor",
                    "suffix": ""
                },
                {
                    "first": "S",
                    "middle": [],
                    "last": "",
                    "suffix": ""
                }
            ],
            "year": 2018,
            "venue": "Antiviral research",
            "volume": "155",
            "issn": "",
            "pages": "67--75",
            "other_ids": {
                "DOI": [
                    "file:/localhost/opt/grobid/grobid-home/tmp/dx.doi.org/10.1016/j.jpha.2020.03.001"
                ]
            }
        },
        "BIBREF26": {
            "ref_id": "b26",
            "title": "Baricitinib as potential treatment for 2019-nCoV acute respiratory disease",
            "authors": [
                {
                    "first": "P",
                    "middle": [],
                    "last": "Richardson",
                    "suffix": ""
                },
                {
                    "first": "I",
                    "middle": [],
                    "last": "Griffin",
                    "suffix": ""
                },
                {
                    "first": "C",
                    "middle": [],
                    "last": "Tucker",
                    "suffix": ""
                }
            ],
            "year": 2020,
            "venue": "Lancet",
            "volume": "395",
            "issn": "",
            "pages": "30--31",
            "other_ids": {}
        },
        "BIBREF27": {
            "ref_id": "b27",
            "title": "COVID-19: combining antiviral and anti-inflammatory treatments",
            "authors": [
                {
                    "first": "J",
                    "middle": [],
                    "last": "Stebbing",
                    "suffix": ""
                },
                {
                    "first": "A",
                    "middle": [],
                    "last": "Phelan",
                    "suffix": ""
                },
                {
                    "first": "I",
                    "middle": [],
                    "last": "Griffin",
                    "suffix": ""
                }
            ],
            "year": null,
            "venue": "Lancet Infect",
            "volume": "2020",
            "issn": "",
            "pages": "",
            "other_ids": {
                "DOI": [
                    "10.1016/S1473-3099(20)30132-8"
                ]
            }
        },
        "BIBREF28": {
            "ref_id": "b28",
            "title": "JAK1/2 inhibition with baricitinib in the treatment of autoinflammatory interferonopathies",
            "authors": [
                {
                    "first": "Gam",
                    "middle": [],
                    "last": "Sanchez",
                    "suffix": ""
                },
                {
                    "first": "A",
                    "middle": [],
                    "last": "Reinhardt",
                    "suffix": ""
                },
                {
                    "first": "S",
                    "middle": [],
                    "last": "Ramsey",
                    "suffix": ""
                }
            ],
            "year": 2018,
            "venue": "J Clin Invest",
            "volume": "128",
            "issn": "",
            "pages": "3041--52",
            "other_ids": {
                "DOI": [
                    "file:/localhost/opt/grobid/grobid-home/tmp/dx.doi.org/10.1016/S1473-3099(20)30132-8"
                ]
            }
        },
        "BIBREF29": {
            "ref_id": "b29",
            "title": "COVID-19: An unexpected indication for antirheumatic therapies?",
            "authors": [
                {
                    "first": "B",
                    "middle": [],
                    "last": "Lucchino",
                    "suffix": ""
                },
                {
                    "first": "Di",
                    "middle": [],
                    "last": "Franco",
                    "suffix": ""
                },
                {
                    "first": "M",
                    "middle": [],
                    "last": "Conti",
                    "suffix": ""
                },
                {
                    "first": "F",
                    "middle": [],
                    "last": "",
                    "suffix": ""
                }
            ],
            "year": null,
            "venue": "Rheumatology",
            "volume": "2020",
            "issn": "",
            "pages": "",
            "other_ids": {}
        }
    },
    "ref_entries": {},
    "back_matter": []
}